Fig. 4

Overall survival of 120 NSCLC patients receiving an immune checkpoint inhibitor (ICI) as part of their therapy. a) Overall survival based upon stratification by cell proliferation for moderately versus combined poorly/highly proliferative. b) Overall survival based upon stratification by cell proliferation for moderately versus poorly and highly proliferative. c) Overall survival based upon stratification by PD-L1 expression levels using TPS ≥ 50% as a cut-off for a positive result. d) Overall survival based upon stratification by strongly positive PD-L1 tumors and proliferation status (PD-L1 TPS ≥ 50% moderately proliferative, PD-L1 TPS ≥ 50% highly or poorly proliferative, PD-L1 TPS ≥ 50% moderately proliferative, PD-L1 TPS ≥ 50% highly or poorly proliferative). Number at risk and p-values are reported